| Literature DB >> 30894571 |
Jae Hwang Cha1, Da Hyun Jung2,3, Jie-Hyun Kim4, Young Hoon Youn4, Hyojin Park4, Jae Jun Park4, Yoo Jin Um4, Soo Jung Park5, Jae Hee Cheon5, Tae Il Kim5, Won Ho Kim5, Hyun Jung Lee6,7.
Abstract
The present study aimed to investigate treatment strategies determining additional treatment after endoscopic resection (ER) of rectal neuroendocrine tumor (NET)s and long-term outcomes of endoscopically resected rectal NETs. We analyzed a total of 322 patients medical records of patients who underwent ER for rectal NETs. Rectal NETs initially resected as polyps and treated with conventional endoscopic mucosal resection (EMR) were observed more frequently in the non-curative group (P = 0.041 and P = 0.012, respectively). After ER, only 44 of the 142 patients (31.0%) who did not meet the criteria for curative resection received additional salvage treatment. In multivariate analysis, lesions diagnosed via biopsies (OR, 0.096; P = 0.002) or suspected as NETs initially (OR, 0.04; P = 0.001) were less likely to undergo additional treatment. Positive lymphovascular invasion (OR 61.971; P < 0.001), positive (OR 75.993; P < 0.001), or indeterminate (OR 13.203; P = 0.001) resection margins were more likely to undergo additional treatment. Although lymph node metastasis was found in 6 patients, none experienced local or metastatic tumor recurrence during the median follow-up of 40.49 months. Long-term outcomes after ER for rectal NETs were excellent. The prognosis showed favorable outcomes regardless of whether patients receive additional salvage treatments.Entities:
Mesh:
Year: 2019 PMID: 30894571 PMCID: PMC6426846 DOI: 10.1038/s41598-019-40668-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and clinical characteristics of patients.
| Total (N = 322) | Risk negative (N = 180) | Risk indeterminate (N = 63) | Risk positive (N = 79) |
| |
|---|---|---|---|---|---|
|
| |||||
| Age at diagnosis (year, mean (SD)) | 47.67 ± 11.47 | 46.80 ± 11.14 | 47.95 ± 12.67 | 48.62 ± 11.25 | 0.469 |
| Gender (%) | 0.143 | ||||
| Male | 207 (64.3) | 113 (62.8) | 47 (74.6) | 47 (59.5) | |
| Female | 115 (35.7) | 67 (37.2) | 16 (25.4) | 32 (40.5) | |
| How to be diagnosed (%) | 0.041 | ||||
| Resected as NET | 190 (59.0) | 102 (56.7) | 46 (73.0) | 42 (53.2) | |
| Diagnosed via biopsy | 102 (31.7) | 64 (35.6) | 13 (20.6) | 25 (31.6) | |
| Resected as Polyps | 30 (9.3) | 14 (7.8) | 4 (6.3) | 12 (15.2) | |
| EUS (%) | 44 (13.7) | 20 (11.1) | 6 (9.5) | 18 (22.8) | 0.024 |
| Pelvic MRI (%) | 15 (4.7) | 8 (4.4) | 2 (3.2) | 5 (6.3) | 0.661 |
| Abdominal imaging (yes, %) | |||||
| Abdominopelvic CT | 299 (92.9) | 170 (94.4) | 55 (87.3) | 74 (93.7) | 0.158 |
| Abdominal US | 40 (12.4) | 19 (10.6) | 9 (14.3) | 12 (15.2) | 0.513 |
| Both | 30 (9.3) | 13 (7.2) | 7 (11.1) | 10 (12.7) | 0.33 |
| Not performed | 13 (4.0) | 4 (2.2) | 6 (9.5) | 3 (3.8) | 0.04 |
| Mode of treatment (%) | 0.012 | ||||
| conventional EMR | 97 (30.1) | 44 (24.4) | 21 (33.3) | 32 (40.5) | |
| modified EMR | 122 (37.9) | 81 (45.0) | 23 (36.5) | 18 (22.8) | |
| ESD | 103 (32.0) | 55 (30.6) | 19 (30.2) | 29 (36.7) | |
|
| |||||
| Pathologic tumor size (mm, mean (SD)) | 4.72 ± 2.44 | 4.14 ± 1.90 | 4.45 ± 1.76 | 6.24 ± 3.24 | <0.001 |
| Group according to tumor size (%) | <0.001 | ||||
| <1 cm | 301 (93.5) | 180 (100.0) | 63 (100.0) | 58 (73.4) | |
| ≥1 cm | 21 (6.5) | 0 (0.0) | 0 (0.0) | 21 (26.6) | |
| Tumor depth (%) | <0.001 | ||||
| Limited to mucosa | 4 (1.2) | 3 (1.7) | 0 (0.0) | 1 (1.3) | |
| Submucosa | 253 (78.6) | 177 (98.3) | 13 (20.6) | 63 (79.7) | |
| Muscularis propria | 3 (0.9) | 0 (0.0) | 0 (0.0) | 3 (3.8) | |
| Indeterminate | 62 (19.3) | 0 (0.0) | 50 (79.4) | 12 (15.2) | |
| Lymphovascular invasion (%) | <0.001 | ||||
| Negative | 291 (90.4) | 180 (100.0) | 57 (90.5) | 54 (68.4) | |
| Positive | 11 (3.4) | 0 (0.0) | 0 (0.0) | 11 (13.9) | |
| Indeterminate | 20 (6.2) | 0 (0.0) | 6 (9.5) | 14 (17.7) | |
| Resection margin (%) | <0.001 | ||||
| Negative | 246 (76.4) | 180 (100.0) | 46 (73.0) | 20 (25.3) | |
| Positive | 57 (17.7) | 0 (0.0) | 0 (0.0) | 57 (72.2) | |
| Indeterminate | 19 (5.9) | 0 (0.0) | 17 (27.0) | 2 (2.5) | |
| Follow-up period (months mean (SD), range) | 40.49 ± 23.56 | 37.29 ± 22.90 | 39.93 ± 21.97 | 48.21 ± 24.98 | 0.002 |
NET, neuroendocrine tumor; CT, computed tomography; US, ultrasonography; EUS, endoscopic ultrasound; EMR, endoscopic mucosal resection;
ESD, endoscopic submucosal dissection; SD, standard deviation.
Outcomes of endoscopic resection of rectal NETs.
| Total (N = 322) | Risk negative (N = 180) | Risk indeterminate (N = 63) | Risk positive (N = 79) |
| |
|---|---|---|---|---|---|
| En bloc resection (%) | |||||
| Yes | 322 (100) | 180 (100.0) | 63 (100.0) | 79 (100.0) | |
| No | 0 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Complete resection (%) | <0.001 | ||||
| Complete (%) | 246 (76.4) | 180 (100.0) | 46 (73.0) | 20 (25.3) | |
| Incomplete (%) | 57 (17.7) | 0 (0.0) | 0 (0.0) | 57 (72.2) | |
| Indeterminate | 19 (5.9) | 0 (0.0) | 17 (27.0) | 2 (2.5) | |
| Complication | 0.293 | ||||
| No | 311 (96.6) | 176 (97.8) | 59 (93.7) | 76 (96.2) | |
| Yes | 11 (3.4) | 4 (2.2) | 4 (6.3) | 3 (3.8) | |
| Surveillance frequency | |||||
| Endoscopic follow up | 1.64 ± 0.92 (0–8) | 1.58 ± 0.80 | 1.44 ± 0.69 | 1.94 ± 1.20 | 0.004 |
| Imaging follow up | 2.89 ± 2.49 (0–17) | 2.51 ± 1.73 | 2.81 ± 2.61 | 3.65 ± 3.36 | 0.012 |
NET, neuroendocrine tumor.
Additional treatment after initial endoscopic resection of rectal NETs.
| n = 44 | n (%) |
|---|---|
| Reasons for additional treatment | |
| ≥1 cm | 6 (13.6) |
| Resection margin (Positive/Indeterminate) | 38 (86.4) |
| Lymphovascular invasion (Positive/Indeterminate) | 15 (34.1) |
| Muscularis propria invasion/Indeterminate | 6 (13.6) |
| Treatment method | |
| ESD | 4 (9.1) |
| modified EMR | 12 (27.3) |
| Coagulation | 6 (13.6) |
| Local excision (TAE/TEO) | 11 (25.0) |
| Radical surgery | 11 (25.0) |
| Treatment method | |
| Local | 33 (75.0) |
| Radical | 11 (25.0) |
| Residual tumor | 1 (2.3) |
| LN metastasis | 6 (13.6) |
NET, neuroendocrine tumor; EMR, endoscopic mucosal resection.
ESD, endoscopic submucosal dissection; TAE, transanal excision.
TEO, transanal endoscopic operation; LN, lymph node.
Risk factors for additional treatment after initial endoscopic resection.
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| Endoscopy only, N = 278 | Endoscopy + additional Tx, N = 44 |
| OR (95% CI) |
| |
| Age at diagnosis (year, mean (SD)) | 47.33 ± 11.49 | 48.35 ± 11.41 | 0.582 | ||
| Gender (%) | 0.358 | ||||
| Male | 176 (63.3) | 31 (70.5) | |||
| Female | 102 (36.7) | 13 (29.5) | |||
| How to be diagnosed (%) | <0.001 | ||||
| Resected as NET | 169 (60.8) | 21 (47.7) | 0.040 (0.007–0.250) | 0.001 | |
| Diagnosed via biopsy | 93 (33.5) | 9 (20.5) | 0.096 (0.022–0.417) | 0.002 | |
| Resected as Polyps | 16 (5.8) | 14 (31.8) | ref | ||
| Mode of treatment (%) | 0.006 | ||||
| conventional EMR | 75 (27.0) | 22 (50.0) | ref | ||
| modified EMR | 112 (40.3) | 10 (22.7) | 1.304 (0.346–4.919) | 0.695 | |
| ESD | 91 (32.7) | 12 (27.3) | 1.124 (0.326–3.871) | 0.853 | |
| Pathologic tumor size (mm, mean (SD), range) | 4.63 ± 2.40 | 5.31 ± 2.62 | 0.085 | ||
| Group according to tumor size (%) | 0.051 | ||||
| <1 cm | 263 (94.6) | 38 (86.4) | ref | ||
| ≥1 cm | 15 (5.4) | 6 (13.6) | 3.035 (0.605–15.235) | 0.177 | |
| Tumor depth (%) | 0.054 | ||||
| Limited to mucosa | 3 (1.1) | 1 (2.3) | ref | ||
| Submucosa | 218 (78.4) | 35 (79.5) | 0.499 (0.028–8.811) | 0.635 | |
| Muscularis propria | 1 (0.4) | 2 (4.5) | 1.401 (0.030–65.233) | 0.863 | |
| Indeterminate | 56 (20.1) | 6 (13.6) | 0.453 (0.021–9.991) | 0.616 | |
| Lymphovascular invasion (%) | <0.001 | ||||
| Negative | 262 (94.2) | 29 (65.9) | ref | ||
| Positive | 5 (1.8) | 6 (13.6) | 61.971 (9.138–420.248) | <0.001 | |
| Indeterminate | 11 (4.0) | 9 (20.5) | 2.026 (0.516–7.971) | 0.312 | |
| Resection margin (%) | <0.001 | ||||
| Negative | 240 (86.3) | 6 (13.6) | ref | ||
| Positive | 24 (8.6) | 33 (75.0) | 75.993 (20.943–275.751) | <0.001 | |
| Indeterminate | 14 (5.0) | 5 (11.4) | 13.203 (2.686–64.902) | 0.001 | |
NET, neuroendocrine tumor; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; SD, standard deviation.
Clinicopathologic characteristics of patients who developed LN metastasis of rectal NETs.
| No. | Sex | Age | Tumor size (mm) | Depth of invasion | LVI | Resection margin | Initial Treatment | Additional Treatment | F/U duration (mo) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 35 | 10 | Submucosa | Positive | Positive | ESD | LAR | 42 | No recur |
| 2 | M | 36 | 10 | Submucosa | Indeterminate | Positive | EMR | LAR | 90 | No recur |
| 3 | M | 60 | 10 | Muscularis propria | Indeterminate | Positive | EMR-C | LAR | 100 | No recur |
| 4 | F | 57 | 10 | Submucosa | Negative | Positive | EMR | LAR | 77 | No recur |
| 5 | M | 41 | 7 | Submucosa | Indeterminate | Positive | ESD | LAR | 72 | No recur |
| 6 | M | 69 | 13 | Muscularis propria | Negative | Positive | ESD | LAR | 63 | No recur |
LVI, lymphovascular invasion; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; NET, neuroendocrine tumor; EMR-C, EMR with a cap; LAR, low anterior resection.
Figure 1Schematic flow chart of the patients in this study. CT, computed tomography; US, ultrasonography; NET, neuroendocrine tumor.